TechInvention Lifecare, a vaccine-focused biotechnology company headquartered in Mumbai, has raised funding from marquee investor Ashish Kacholia.
The investment is to primarily fund TechInvention’s upcoming vaccine manufacturing facility in Navi Mumbai. The facility is designed to scale up and manufacture vaccines from its robust R&D portfolio of vaccine candidates encompassing contemporary platforms such as recombinant subunit, conjugates, VLP (virus-like particles), adenoviral vector, & mRNA platforms.
Founded in 2016, TechInvention Lifecare provides vaccines, diagnostics, and bio-therapeutics services. Its suite of services includes expertise in contract manufacturing, project feasibility, technology licensing, WHO prequalification support, design engineering, regulatory affairs, clinical research, and intellectual property assistance.
Ashish Kacholia said, “We are delighted to support TechInvention in getting life-saving, innovative vaccines commercialized & reach millions across India & beyond. The founders of TechInvention are techno-commercially savvy, & together we hope to build a high-quality business over the next few years.”
Syed S. Ahmed, Founder & CEO of TechInvention Lifecare, said, “We are delighted to have Mr Kacholia’s confidence in our vision, & his participation is an assurance of the advancement of our Manufacturing facility project titled –‘Global Collaborative Centre for Medical Counter Measures (GCMC). His belief in our mission reinforces India’s role as a trusted enabler of equitable health solutions for low and middle-income countries (LMICs).”
